Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.44 |
| ▸ | CA2 | P00918 | 9/20 | 0.44 |
| ▸ | CA9 | Q16790 | 8/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717340 | 1.00 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1276367 | 1.00 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL721790 | 1.00 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL11044079 | 0.92 | CA1 (0.40) | CA1CA2CA9CA12CA7 | |
| SCHEMBL28416633 | 0.86 | CA1 (0.42) | CA1CA2CA9CA12CA7 | |
| SCHEMBL28424856 | 0.86 | CA1 (0.42) | CA1CA2CA9CA12CA7 | |
| SCHEMBL987798 | 0.85 | CA1 (0.41) | CA1CA2CA9CA12CA7 | |
| SCHEMBL723644 | 0.85 | CA1 (0.41) | CA1CA2CA9CA12CA7 | |
| SCHEMBL987423 | 0.85 | CA1 (0.41) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1276368 | 0.85 | CA1 (0.41) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140044788-A1 | Solid Oral Formulations of a Pyridopyrimidinone | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | claimed |
| US-20110287069-A1 | SOLID ORAL FORMULATIONS OF A PYRIDOPYRIMIDINONE | NOVARTIS AG (CH) | 2011-11-24 | — | — | US | claimed |
| WO-2010088336-A1 | SOLID ORAL FORMULATIONS OF A PYRIDOPYRIMIDINONE | NOVARTIS AG (CH) | 2010-08-05 | — | — | WO | claimed |
| WO-2004098562-A2 | CONTROLLED RELEASE SOLID DOSAGE NIFEDIPINE FORMULATIONS | NOVEON IP HOLDINGS CORP. (US) | 2004-11-18 | — | — | WO | claimed |
| US-20040219210-A1 | Controlled release solid dosage nifedipine formulations | LUBRIZOL ADVANCED MATERIALS, INC. | 2004-11-04 | — | — | US | claimed |
| WO-2003084513-A1 | CONTROLLED RELEASE SOLID DOSAGE CARBAMAZEPINE FORMULATIONS | NOVEON IP HOLDINGS CORP. (US) | 2003-10-16 | — | — | WO | claimed |
| US-6572889-B1 | Crosslinked polymer of an unsaturated acid | NOVEON IP HOLDINGS CORP. | 2003-06-03 | — | — | US | claimed |
| EP-3826627-B1 | ORALLY ADMINISTERABLE PHARMACEUTICAL DOSAGE FORM WITH MODIFIED RELEASE | BAYER AG (DE) | 2023-10-18 | — | — | EP | disclosed |
| US-20220257547-A1 | ORALLY ADMINISTRABLE MODIFIED-RELEASE PHARMACEUTICAL DOSAGE FORM | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-08-18 | — | — | US | disclosed |
| US-11344519-B2 | Orally administrable modified-release pharmaceutical dosage form | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-31 | — | — | US | disclosed |
| US-20210283046-A1 | PHARMACEUTICAL DOSAGE FORM WHICH CAN BE ADMINISTERED ORALLY AND HAS MODIFIED RELEASE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-09-16 | — | — | US | disclosed |
| US-20210113504-A1 | ORALLY ADMINISTRABLE MODIFIED-RELEASE PHARMACEUTICAL DOSAGE FORM | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-22 | — | — | US | disclosed |
| CN-112469398-A | Pharmaceutical dosage form for oral administration with a sustained release effect | 拜耳公司 | 2021-03-09 | — | — | CN | disclosed |
| US-RE34990-E | Anticonvulsants, treatment of epilepsy, carbamazepine | CIBA-GEIGY CORPORATION (US) | 1995-07-04 | — | — | US | disclosed |
| US-5344825-A | Cationic divinylbenzene-styrene copolymer with exchangeable phosphonic acid methylaminomethyl groups and sodium salts | CIBA-GEIGY CORP. (US) | 1994-09-06 | — | — | US | disclosed |
| US-5284662-A | Core of carbamazepine, crystal habit modifiers, hydroxyalkyl c celluloses, sugar alcohol, and mono- or disacdaride, semipermeable wall and hole in wall | CIBA-GEIGY CORP. (US) | 1994-02-08 | — | — | US | disclosed |
| US-5096717-A | Disodium 3-amino-1-hydroxypropane-1,1-diphosphonate; controlle d release; oral administration; hydrophilic, elastic coating a nd gastric juice-resistant, intestinal juice-soluble coating; granulation and coating | CIBA-GEIGY CORPORATION (US) | 1992-03-17 | — | — | US | disclosed |
| US-4996058-A | Sustained release, drug delivery | CIBA-GEIGY CORPORATION (US) | 1991-02-26 | — | — | US | disclosed |
| US-4992278-A | Cellulose casing, core containing hydrophilic polymeric swelling agent blend of vinyl acetate-vinylpyrrolidone copolymer asnd polyoxyethylene glycol | CIBA-GEIGY CORPORATION (US) | 1991-02-12 | — | — | US | disclosed |
| US-4857336-A | Oral therapeutic system having systemic action | CIBA-GEIGY CORPORATION (US) | 1989-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140044788-A1 | Solid Oral Formulations of a Pyridopyrimidinone | PLPBP, DPYD, SLC7A1 | CA1 4656/4885CA2 2941/4885CA9 4068/4885 |
| US-20110287069-A1 | SOLID ORAL FORMULATIONS OF A PYRIDOPYRIMIDINONE | PLPBP, DPYD, SLC7A1 | CA1 4656/4885CA2 2941/4885CA9 4068/4885 |
| US-20210113504-A1 | ORALLY ADMINISTRABLE MODIFIED-RELEASE PHARMACEUTICAL DOSAGE FORM | GLS, FABP3, TNNC1 | CA1 2140/4885CA2 378/4885CA9 1188/4885 |
| US-20220257547-A1 | ORALLY ADMINISTRABLE MODIFIED-RELEASE PHARMACEUTICAL DOSAGE FORM | GLS, FABP3, TNNC1 | CA1 2140/4885CA2 378/4885CA9 1188/4885 |
| US-11344519-B2 | Orally administrable modified-release pharmaceutical dosage form | GLS, FABP3, TNNC1 | CA1 2140/4885CA2 378/4885CA9 1188/4885 |
| US-20210283046-A1 | PHARMACEUTICAL DOSAGE FORM WHICH CAN BE ADMINISTERED ORALLY AND HAS MODIFIED RELEASE | GLS, FABP3, ATP6V1B1 | CA1 2915/4885CA2 464/4885CA9 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.